Mark A Dickson

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Invest New Drugs 33:349-56. 2015
  2. doi request reprint Systemic treatment options for radiation-associated sarcomas
    Mark A Dickson
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E 66th St, New York, NY, 10065, USA
    Curr Treat Options Oncol 15:476-81. 2014
  3. doi request reprint Molecular pathways: CDK4 inhibitors for cancer therapy
    Mark A Dickson
    Author s Affiliation Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York
    Clin Cancer Res 20:3379-83. 2014
  4. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
  5. pmc Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
    M A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 24:252-7. 2013
  6. pmc Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 132:1711-7. 2013
  7. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
  8. ncbi request reprint MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
    Marta Kovatcheva
    The Louis V Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Oncotarget 6:8226-43. 2015
  9. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012

Detail Information

Publications9

  1. doi request reprint Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Invest New Drugs 33:349-56. 2015
    ..Conclusions XL281 was generally well tolerated and the MTD was established at 150 mg/day. Partial responses and clinical benefit were observed in several patients. Tumor biopsies demonstrated effective target inhibition. ..
  2. doi request reprint Systemic treatment options for radiation-associated sarcomas
    Mark A Dickson
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 300 E 66th St, New York, NY, 10065, USA
    Curr Treat Options Oncol 15:476-81. 2014
    ..More prospective research is needed on how radiation-associated sarcomas respond to systemic therapy. Future clinical trials of new agents in sarcoma should identify and include patients with radiation-associated sarcoma...
  3. doi request reprint Molecular pathways: CDK4 inhibitors for cancer therapy
    Mark A Dickson
    Author s Affiliation Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York
    Clin Cancer Res 20:3379-83. 2014
    ..Major efforts are under way to develop biomarkers of response, understand potential mechanisms of resistance, and develop rational combinations of CDK4 inhibitors with chemotherapy and other targeted drugs...
  4. pmc Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    Mark A Dickson
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 31:2024-8. 2013
    ..In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS...
  5. pmc Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
    M A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Oncol 24:252-7. 2013
    ..BIIB021 is an oral non-ansamycin HSP90 inhibitor. We carried out a phase II study of BIIB021 in patients with GIST refractory to imatinib and sunitinib...
  6. pmc Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Cancer 132:1711-7. 2013
    ..These findings highlight the consistent though incomplete activity of mTOR inhibitors in the treatment of PEComas...
  7. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  8. ncbi request reprint MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
    Marta Kovatcheva
    The Louis V Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Oncotarget 6:8226-43. 2015
    ..These insights identify MDM2 and ATRX as new regulators controlling geroconversion, the process by which quiescent cells become senescent, and this insight may be exploited to improve the activity of CDK4i in cancer therapy. ..
  9. pmc The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial
    Jason J Luke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2638-47. 2012
    ..As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas...